Eisai Realigns US Operations - Reduces its Workforce by 25%

Eisai Inc., a US subsidiary of Eisai Co., Ltd., has announced plans to realign its operations in the US. As part of this restructuring, Eisai Inc. will reduce its workforce by approximately 25% across various US functions. This realignment supports Eisai's desire to create a more efficient and focused organization.

"The actions we are taking will ensure Eisai stays competitive in a rapidly changing business environment," said Yuji Matsue, Chairman and CEO of Eisai Inc. "Eisai remains fully committed to the US market and will continue to serve the needs of patients and their families by developing and marketing important new treatments that help to satisfy unmet medical needs. Through this realignment, we will be able to redeploy our resources to support the development of our priority late-stage compounds and our current product portfolio."

The new structure is expected to be in place by 1 May 2015. Eisai's US operations include R&D, manufacturing, sales and marketing, and administrative functions. The company does not have plans to close any of its main offices or facilities.

"This decision was difficult," said Shaji Procida, President and COO of Eisai Inc. "We are grateful to our colleagues, each of whom has played an important role in helping us fulfil our human health care (hhc) mission of bringing important new medicines to patients. We are aware of the impact that our reorganization will have on some employees and will work with them to ensure that their transition is as smooth as possible."